2024 年日本弥散性血管内凝血管理临床实践指南。第 1 部分:败血症。

IF 1.7 4区 医学 Q3 HEMATOLOGY
Kazuma Yamakawa, Kohji Okamoto, Yoshinobu Seki, Takayuki Ikezoe, Takashi Ito, Toshiaki Iba, Satoshi Gando, Noritaka Ushio, Takaaki Totoki, Takeshi Wada, Hidesaku Asakura, Hiroyasu Ishikura, Mitsuhiro Uchiba, Toshimasa Uchiyama, Kaoru Kawasaki, Noriaki Kawano, Shigeki Kushimoto, Shin Koga, Yuichiro Sakamoto, Toshihisa Tamura, Kenji Nishio, Mineji Hayakawa, Takeshi Matsumoto, Seiji Madoiwa, Toshihiko Mayumi, Shinya Yamada, Hideo Wada
{"title":"2024 年日本弥散性血管内凝血管理临床实践指南。第 1 部分:败血症。","authors":"Kazuma Yamakawa, Kohji Okamoto, Yoshinobu Seki, Takayuki Ikezoe, Takashi Ito, Toshiaki Iba, Satoshi Gando, Noritaka Ushio, Takaaki Totoki, Takeshi Wada, Hidesaku Asakura, Hiroyasu Ishikura, Mitsuhiro Uchiba, Toshimasa Uchiyama, Kaoru Kawasaki, Noriaki Kawano, Shigeki Kushimoto, Shin Koga, Yuichiro Sakamoto, Toshihisa Tamura, Kenji Nishio, Mineji Hayakawa, Takeshi Matsumoto, Seiji Madoiwa, Toshihiko Mayumi, Shinya Yamada, Hideo Wada","doi":"10.1007/s12185-024-03896-9","DOIUrl":null,"url":null,"abstract":"<p><p>The Japanese Society on Thrombosis and Hemostasis (JSTH) published the first-ever disseminated intravascular coagulation (DIC) guidelines in 2009. Fifteen years later, the JSTH developed new guidelines covering DIC associated with various underlying conditions. These guidelines were developed in accordance with the GRADE system to determine the strength of the recommendations and certainty of the evidence. This article was drafted as Part 1 of an overall DIC guideline covering various underlying conditions, with sepsis as the subject. In this section, seven key clinical issues (questions) are set. Question 1, regarding DIC diagnosis, introduces several diagnostic criteria, such as the JAAM-2, ISTH overt, SIC, and JSTH DIC criteria and recommends choosing the appropriate diagnostic criteria for DIC based on an understanding of their diagnostic properties. For pharmacotherapy in DIC patients with sepsis, we recommend the administration of antithrombin (Question 2) and recombinant thrombomodulin (Question 3) (both GRADE 1B). However, we do not make a clear recommendation regarding the administration of heparin (Question 6) and serine protease inhibitors (Question 7) because of the lack of evidence. Combination therapy, order of administration, and other administration methods for antithrombin and recombinant thrombomodulin are proposed as important future research questions (Questions 4 and 5).</p>","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.7000,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024. Part 1: sepsis.\",\"authors\":\"Kazuma Yamakawa, Kohji Okamoto, Yoshinobu Seki, Takayuki Ikezoe, Takashi Ito, Toshiaki Iba, Satoshi Gando, Noritaka Ushio, Takaaki Totoki, Takeshi Wada, Hidesaku Asakura, Hiroyasu Ishikura, Mitsuhiro Uchiba, Toshimasa Uchiyama, Kaoru Kawasaki, Noriaki Kawano, Shigeki Kushimoto, Shin Koga, Yuichiro Sakamoto, Toshihisa Tamura, Kenji Nishio, Mineji Hayakawa, Takeshi Matsumoto, Seiji Madoiwa, Toshihiko Mayumi, Shinya Yamada, Hideo Wada\",\"doi\":\"10.1007/s12185-024-03896-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The Japanese Society on Thrombosis and Hemostasis (JSTH) published the first-ever disseminated intravascular coagulation (DIC) guidelines in 2009. Fifteen years later, the JSTH developed new guidelines covering DIC associated with various underlying conditions. These guidelines were developed in accordance with the GRADE system to determine the strength of the recommendations and certainty of the evidence. This article was drafted as Part 1 of an overall DIC guideline covering various underlying conditions, with sepsis as the subject. In this section, seven key clinical issues (questions) are set. Question 1, regarding DIC diagnosis, introduces several diagnostic criteria, such as the JAAM-2, ISTH overt, SIC, and JSTH DIC criteria and recommends choosing the appropriate diagnostic criteria for DIC based on an understanding of their diagnostic properties. For pharmacotherapy in DIC patients with sepsis, we recommend the administration of antithrombin (Question 2) and recombinant thrombomodulin (Question 3) (both GRADE 1B). However, we do not make a clear recommendation regarding the administration of heparin (Question 6) and serine protease inhibitors (Question 7) because of the lack of evidence. Combination therapy, order of administration, and other administration methods for antithrombin and recombinant thrombomodulin are proposed as important future research questions (Questions 4 and 5).</p>\",\"PeriodicalId\":13992,\"journal\":{\"name\":\"International Journal of Hematology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2024-12-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Hematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s12185-024-03896-9\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12185-024-03896-9","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

日本血栓与止血学会(JSTH)于 2009 年首次发布了弥散性血管内凝血(DIC)指南。15 年后,日本血栓与止血学会又制定了新的指南,涵盖了与各种基础疾病相关的 DIC。这些指南是根据 GRADE 系统制定的,以确定建议的力度和证据的确定性。本文是以败血症为主题,作为涵盖各种基础疾病的整体 DIC 指南的第一部分而起草的。本部分设置了七个关键临床问题(提问)。问题 1 涉及 DIC 诊断,介绍了几种诊断标准,如 JAAM-2、ISTH overt、SIC 和 JSTH DIC 标准,并建议在了解其诊断特性的基础上选择合适的 DIC 诊断标准。对于脓毒症 DIC 患者的药物治疗,我们建议使用抗凝血酶(问题 2)和重组血栓调节蛋白(问题 3)(均为 GRADE 1B)。但是,由于缺乏证据,我们没有就肝素(问题 6)和丝氨酸蛋白酶抑制剂(问题 7)的使用提出明确建议。抗凝血酶和重组血栓调节蛋白的联合疗法、给药顺序和其他给药方法被列为今后的重要研究课题(问题 4 和 5)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024. Part 1: sepsis.

The Japanese Society on Thrombosis and Hemostasis (JSTH) published the first-ever disseminated intravascular coagulation (DIC) guidelines in 2009. Fifteen years later, the JSTH developed new guidelines covering DIC associated with various underlying conditions. These guidelines were developed in accordance with the GRADE system to determine the strength of the recommendations and certainty of the evidence. This article was drafted as Part 1 of an overall DIC guideline covering various underlying conditions, with sepsis as the subject. In this section, seven key clinical issues (questions) are set. Question 1, regarding DIC diagnosis, introduces several diagnostic criteria, such as the JAAM-2, ISTH overt, SIC, and JSTH DIC criteria and recommends choosing the appropriate diagnostic criteria for DIC based on an understanding of their diagnostic properties. For pharmacotherapy in DIC patients with sepsis, we recommend the administration of antithrombin (Question 2) and recombinant thrombomodulin (Question 3) (both GRADE 1B). However, we do not make a clear recommendation regarding the administration of heparin (Question 6) and serine protease inhibitors (Question 7) because of the lack of evidence. Combination therapy, order of administration, and other administration methods for antithrombin and recombinant thrombomodulin are proposed as important future research questions (Questions 4 and 5).

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.90
自引率
4.80%
发文量
223
审稿时长
6 months
期刊介绍: The International Journal of Hematology, the official journal of the Japanese Society of Hematology, has a long history of publishing leading research in hematology. The journal comprises articles that contribute to progress in research not only in basic hematology but also in clinical hematology, aiming to cover all aspects of this field, namely, erythrocytes, leukocytes and hematopoiesis, hemostasis, thrombosis and vascular biology, hematological malignancies, transplantation, and cell therapy. The expanded [Progress in Hematology] section integrates such relevant fields as the cell biology of stem cells and cancer cells, and clinical research in inflammation, cancer, and thrombosis. Reports on results of clinical trials are also included, thus contributing to the aim of fostering communication among researchers in the growing field of modern hematology. The journal provides the best of up-to-date information on modern hematology, presenting readers with high-impact, original work focusing on pivotal issues.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信